CA-ENCHROMA
16.7.2024 13:01:33 CEST | Business Wire | Press release
EnChroma® — creators of glasses for color blindness — today announced that organizations and businesses can now sign up to support International Color Blindness Awareness Month™ 2024. Every September, hundreds of organizations come together to promote ‘color accessibility’ and inclusion for the one in 12 men (8%) and one in 200 women (.5%) who are color blind; an estimated 13 million in the United States; 30 million in Europe; and 350 million worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716891549/en/
Depiction of red-green color blind and normal color vision views of colorful buildings in Amsterdam. (Photo: Business Wire)
Anytime in September, hundreds of museums, universities, businesses, libraries, schools, park systems, tourism agencies, philanthropic groups and others will make social media posts, disseminate information, and engage in other activities to educate the public about the prevalence and effects of Color Vision Deficiency (CVD).
“Awareness of just how common color blindness is and how significant its impacts are, still remains low amongst employers, educators, parents and the general public,” said Erik Ritchie, CEO of EnChroma. “From color confusion in the workplace, at school, when enjoying sports and the outdoors, or when simply doing daily activities can be frustrating for those with CVD. This year, we hope even more organizations will support International Color Blindness Awareness Month to both educate and advocate on behalf of the color blind.”
While people with normal color vision see over one million shades of color, the red-green color blind only see an estimated 10% of hues and shades. As a result, colors can appear dull, indistinct and difficult to discern; red can appear brown; green can look tan, gray or yellow; and purple and blue look similar.
Click here to see more images depicting color blindness.
Last year, over 250 organizations around the world used their voices and platforms in support including multinational corporations such as Honeywell Aerospace, Siemens Energy and Faber-Castell; renowned museums such as the Centre Pompidou and the Georgia O’Keeffe Museum; universities such as the University of North Carolina, Boston University and North Carolina State University; state and national parks such as Friends of Kauai Wildlife Refuges and Alaska State Parks; the Atlanta Botanical Garden; nature advocates like the Audubon Nature Institute; and groups such as Travel Oregon, Lions and Kiwanis clubs, and the Boy Scouts of America.
How to Apply
Organizations and businesses can sign up here to commit to making at least one social media post, or undertake any other activity, that promotes color blindness awareness in September, using any of an array of customizable images and templates. Do as little as make one social media post using a customizable template or create your own post(s) with easy-to-use tools. Participating organizations can choose to receive two pairs of EnChroma glasses to give away to color blind students, customers, staff or visitors. The offer to give away EnChroma glasses is not available to individuals.
EnChroma Color Accessibility Program™
EnChroma is the lead advocate for ‘color accessibility,’ helping more than 400 universities, K-12 schools, state and national parks, libraries, museums, tourism departments, attractions and other organizations purchase and loan EnChroma glasses to color blind students and guests. EnChroma donates a pair of glasses for each pair an organization buys to lend to the public or students. The program is also open to employers. Scenic viewers adapted for the color blind are also available and in use by park systems across 25 states.
EnChroma glasses are engineered with special optical filters that help the red-green color blind experience an expanded range of colors more vibrantly and distinctly to make schoolwork that involves color, art, nature and other experiences more ‘color accessible.’ The glasses do not deliver full color vision and results and reaction times vary. EnChroma glasses enhance color for approximately 80% of people with deuteranomalous or protanomalous red-green color blindness who have all three of their color sensing cones. Read this study by UC Davis about the glasses.
About EnChroma
Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for red-green color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with red-green color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. Call 510-497-0048 or visit enchroma.com for more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716891549/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
